Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Omeros Corporation
  6. Summary
    OMER   US6821431029

OMEROS CORPORATION

(OMER)
  Report
Real-time Estimate Cboe BZX  -  10:18 2022-08-10 am EDT
6.865 USD   +10.73%
08/09OMEROS : Q2 Earnings Snapshot
AQ
08/09OMEROS : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/09OMEROS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/04/2022 08/05/2022 08/08/2022 08/09/2022 08/10/2022 Date
5.73(c) 6.83(c) 6.75(c) 6.2(c) 6.915 Last
620 763 999 206 861 162 637 134 218 165 Volume
+6.51% +19.20% -1.17% -8.15% +11.53% Change
More quotes
Estimated financial data (e) (USD)
Sales 2022 - - -
Net income 2022 -152 M - -
Net Debt 2022 263 M - -
P/E ratio 2022 -3,06x
Yield 2022 -
Sales 2023 3,12 M - -
Net income 2023 -138 M - -
Net Debt 2023 137 M - -
P/E ratio 2023 -3,39x
Yield 2023 -
Capitalization 389 M 389 M -
EV / Sales 2022 -
EV / Sales 2023 169x
Nbr of Employees 213
Free-Float 96,0%
More Financials
Company
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic diseases, including complement-mediated diseases and cancers related to dysfunction of the immune system, as well as addictive and compulsive disorders. Its lead lead MASP-2 inhibitor narsoplimab... 
Read more
Sector
Pharmaceuticals
Calendar
08/11Earnings Release
More about the company
Ratings of Omeros Corporation
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
D+
More Ratings
All news about OMEROS CORPORATION
08/09OMEROS : Q2 Earnings Snapshot
AQ
08/09OMEROS : Reports Second Quarter 2022 Financial Results - Form 8-K
PU
08/09OMEROS CORP MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF..
AQ
08/09Omeros Corporation Reports Second Quarter 2022 Financial Results
BU
08/09Omeros Corporation Reports Earnings Results for the Second Quarter and Six Months Ended..
CI
08/04Omeros Corporation to Announce Second Quarter Financial Results on August 9, 2022
BU
07/29SECTOR UPDATE : Health Care Stocks Remain Lower Ahead of Friday's Close
MT
07/29SECTOR UPDATE : Health Care Stocks Retreat in Friday Trading
MT
07/29Omeros Says FDA Grants Orphan Drug Designation to OMS906 to Treat Blood Cell Disease
MT
07/29FDA Grants Orphan Drug Designation to Omeros' MASP-3 Inhibitor OMS906 for Treatment of ..
BU
07/29Omeros Gets FDA Orphan-Drug Designation for OMS906 in PNH
DJ
06/24OMEROS CORP : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
06/24OMEROS CORPORATION(NASDAQGM : OMER) dropped from Russell 2500 Index
CI
06/24OMEROS CORPORATION(NASDAQGM : OMER) dropped from Russell 2500 Growth Index
CI
06/24OMEROS CORPORATION(NASDAQGM : OMER) added to Russell Microcap Growth Index
CI
More news
News in other languages on OMEROS CORPORATION
08/09Omeros Corporation annonce ses résultats pour le deuxième trimestre et le semestre clos..
07/29MISE À JOUR SECTORIELLE : Les actions du secteur de la santé restent en baisse avant la cl..
07/29MISE À JOUR SECTORIELLE : Les actions du secteur de la santé reculent dans les échanges de..
07/29Omeros déclare que la FDA accorde la désignation de médicament orphelin à l'OMS906 pour..
06/08Les actions d'Omeros chutent après la rétrogradation de BofA
More news
Analyst Recommendations on OMEROS CORPORATION
More recommendations
Chart OMEROS CORPORATION
Duration : Period :
Omeros Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends OMEROS CORPORATION
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Last Close Price 6,20 $
Average target price 12,17 $
Spread / Average Target 96,2%
EPS Revisions
Managers and Directors
Gregory A. Demopulos Chairman, President & Chief Executive Officer
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP
George A. Gaitanaris Chief Scientific Officer & Vice President-Science
J. Steven Whitaker Chief Medical Officer & Vice President
Thomas J. Cable Lead Independent Director
Sector and Competitors
1st jan.Capi. (M$)
OMEROS CORPORATION-3.58%389
CSL LIMITED2.15%99 702
SAMSUNG BIOLOGICS CO.,LTD.-0.11%49 125
WUXI BIOLOGICS (CAYMAN) INC.-19.50%40 472
BIOGEN INC.-9.31%31 575
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-22.38%22 915